A new randomised, double-blind clinical trial suggests the diabetes and obesity drug semaglutide may also act as an anti-ageing therapy. Researchers enrolled 108 adults with HIV-associated lipohypertrophy, assigning half to weekly semaglutide injections and half to a placebo for 32 weeks. Blood analyses showed participants receiving semaglutide became an average of 3.1 years biologically younger, measured across multiple DNA-methylation ‘epigenetic clocks’. The placebo group recorded no significant change. Ageing slowed across 11 organ-specific clocks, with the brain and inflammatory system appearing almost five years younger by the end of the study. The findings, posted as a preprint, mark the first human randomised trial to report a reversal of biological age using a GLP-1 drug better known for glucose and weight control. While scientists say the results strengthen the case for repurposing semaglutide for longevity, they caution that broader use as an anti-ageing therapy is premature until larger, peer-reviewed studies confirm the benefits and assess long-term safety.